From June 5th to June 8th in accordance with the PST, , the BIO International Convention, a leading biotechnology exhibition, took place successfully in Boston Convention and Exhibition Center. MicuRx Pharmaceuticals (Stock code: 688373 SH.) made its appearance at the convention. Mr. Jerry Li, CFO of MicuRx Pharmaceuticals and President of MicuRx Pharmaceuticals USA, participated in the company's exhibition session and introduced the company's profile and R&D pipeline to the attendees. Established in 1993, BIO is an annual meeting of the global biotechnology innovation organization in the United States. It is the largest, most professional, and influential biotechnology event in the world. The conference focuses not only on trade transactions but also on exhibitions and meetings, providing a comprehensive platform for companies, technology parks, and research institutions from around the world to promote and showcase their innovations. At the afternoon of June 7th PST, Mr. Jerry Li, President of MicuRx Pharmaceuticals USA, attended the event and provided detailed information to the attendees regarding company's R&D progress, pipeline, and commercialization plans in China, the United States, and Europe. Currently, the core product of company, MRX-4 and Contezolid Tablets, are undergoing global multi-center Phase III sequential trials in an orderly manner. Both…

Recently, the selection for the 3rd Pharmaceutical Innovation for Public Welfare Awards, organized by Securities Times, came to a close. After self-recommendation, recommendations, online voting, and expert evaluations, the list of winners was officially announced. In this edition of the awards, MicuRx Pharmaceuticals' Contezolid tablets R&D Team was recognized as one of the "Top Ten Pharmaceutical Innovation Research Teams," affirming company's research and development capabilities and commercial value. Established in 2021, the Pharmaceutical Innovation for Public Welfare Awards aims to recognize and reward outstanding innovative drug projects, companies, institutions, and scientists who have made significant progress in the past year. The awards rely on the "People's Finance·Innovative Drug Index" database for evaluation. Contezolid Tablets is oxazolidinone antibiotics and represent a new generation of antibacterial drugs independently designed and developed by MicuRx Pharmaceuticals. It is used to treat Gram-positive bacterial infections. Building upon the previous generation of antibacterial drug Linezolid, MicuRx's R&D team made changes to the molecular structure of the drug, creatively alleviating spinal cord suppression toxicity. Clinical trials have also demonstrated that Contezolid Tablets achieve both effectiveness and safety. They were approved for market launch in China in June 2021 and entered the National Medical Insurance Negotiation in December…

On May 11, 2023, on the occasion of the 7th "China Brand," the "2023 New China Health Industry and Capital Summit Forum," hosted by Economic Information Daily, grandly opened in Deqing, Zhejiang. MicuRx Pharmaceuticals' product, Contezolid tablets, was successfully selected as an "Excellent Case of Innovative Health Product," fully showing MicuRx Pharmaceuticals’ innovative capabilities and product value. This event was jointly organized by Xinhua News Agency, government of Zhejiang Province, and China Brand Building Promotion Association, among other institutions. Its aim was to show the high-quality development in the health industry and promote greater responsibilities and contributions of health enterprises in the new era. The event attached great importance to high-quality health cases and set up the "Excellent Case of Health Industry" evaluation segment. Considering various dimensions such as technological barriers, market performance, brand building, and corporate culture, MicuRx Pharmaceuticals' contezolid tablets were recognized as an "Excellent Case of Innovative Health Product." MicuRx Pharmaceuticals' main product is Contezolid tablets (Youxitai), which belongs to the oxazolidinone class of antibiotics and was approved for market launch in China in June 2021. Contezolid tablets has made molecular structural improvements to the previous generation of super-antibiotics, incorporating an innovative structure. This structure enables a…

On April 12, 2023, Shanghai MicuRx Pharmaceuticals Co., Ltd. (stock code: 688373.SH) announced the initiation of the first center for the clinical trial of Contezolid tablets in pediatric patients with complicated Skin and Soft Tissue Infections. On October 26, 2022, MicuRx obtained the approval notice for supplementary application of drug clinical trials from the National Medical Products Administration, allowing the expansion of Contezolid tablets' indications to pediatric patients with complicated skin and soft tissue infections. Contezolid tablets is a new generation of azole antibacterial drugs independently designed and developed by MicuRx Pharmaceutical. They are used for the treatment of infections caused by multidrug-resistant Gram-positive bacteria. It is reported that Contezolid tablets have implemented several pioneering measures in clinical trials of antibacterial drugs in China, setting industry benchmarks for clinical trials in the field of innovative antimicrobial drugs. The success of Contezolid tablets in clinical trials in China has laid a solid foundation for elevating clinical trial standards and improving product quality in the future development of innovative antimicrobial drugs in China. By the end of 2022, Contezolid tablets had covered 309 hospitals in 50 cities nationwide, with formal access and bulk procurement in over 70 hospitals. Hospital channel sales accounted…

On April 4, 2023, Shanghai MicuRx Pharmaceuticals Co., Ltd. (stock code: 688373.SH) announced the initiation of the first domestic center for the global Phase III clinical trial of its independently developed antibacterial drug, MRX-4, in sequential combination with orally administered Contezolid tablets for the treatment of diabetic foot infections caused by Gram-positive multidrug-resistant bacteria. Contezolid tablets and MRX-4 are innovative azole antimicrobial drugs with global intellectual property rights developed by MicuRx Pharmaceuticals. Contezolid tablets was approved by the National Medical Products Administration (NMPA) on June 1, 2021, for the treatment of complicated skin and soft tissue infections, marking the first global approval of this drug. MRX-4, developed based on Contezolid tablets, serves as a prodrug of Contezolid. After the approval of MRX-4 for intravenous administration, clinical physicians can choose to independently use intravenous MRX-4 or sequentially administer contezolid tablets for the treatment of infections caused by drug-resistant Gram-positive bacteria. The international multi-center Phase III clinical trial studying the sequential administration of MRX-4 and Contezolid tablets for the treatment of diabetic foot infections is a randomized, double-blind study. Its primary objective is to evaluate the safety and efficacy of MRX-4/Contezolid tablets in moderate to severe diabetic foot infections (DFI). The trial…

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointed Regis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, MicuRx Pharmaceuticals, Inc. He oversees new drug development programs and clinical activities in the United States, Europe and other regions. Dr. Vilchez earned an M.D. from the Universidad Autónoma de Centro América in Costa Rica and a Ph.D. from Baylor College of Medicine in Houston, Texas, the United States. He completed an internal medicine residency at Robert Wood Johnson Medical School, a clinical infectious diseases fellowship at the University of Pittsburgh, and a molecular virology fellowship at Baylor College of Medicine. Prior to entering the biopharmaceutical industry, Dr. Vilchez was full time faculty in the Departments of Medicine and Molecular Virology & Microbiology at Baylor College of Medicine. Dr. Vilchez has served in multiple R&D roles at Boehringer Ingelheim, Merck, Roche, Abbott/AbbVie, Mallinckrodt Pharmaceuticals and other smaller biotechnology companies. In those roles, Dr. Vilchez has been a key contributor to the global development of new therapies such as Vicriviroc, Victrelis, Viekirax, Technivie, Ocaliva, Terlivaz, and StrataGraft. Dr. Vilchez has co-authored more than 100 peer-reviewed scientific…

Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. (“MicuRx Pharmaceuticals”, SHSE: 688373) announced the completion of the first subject administration of MRX-8, its independently-developed new drug against gram-negative drug-resistant bacteria, in the Phase I clinical trial of China, which marks the entry to the substantial stage in the clinical development of MRX-8 in China. MRX-8, a polymyxin-class drug, primarily used to treat infections caused by multidrug-resistant Gram-negative bacteria, has the same antibacterial spectrum as the existing drugs colistin and polymyxin B, and is also therapeutic against carbapenem-resistant negative bacteria, a superbug and the most “serious threat” to human health as defined by the World Health Organization. The Phase 1 clinical trials of MRX-8 has completed in the US previously. The ongoing Phase 1 clinical trial in China is a randomized, double-blind, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetic profile of MRX-8 administered intravenously in healthy Chinese subjects and is expected to be completed in 2023. MicuRx Pharmaceuticals has carried out targeted development based on the problems on safety and manufacturing process existing in polymyxins. In the early stage of compound design, combining with antibacterial activity screening, simultaneous structure-activity relationship and structure-toxicity relationship study, the company introduced innovative “soft drug”…

Poster Summary The primary efficacy and safety of MRX-1/MRX-4 are similar across gender and BMI Subjects with mild and moderate renal impairment achieve comparable primary efficacy and safety to subjects with normal renal function, without dose adjustment for MRX-1/MRX-4 The platelet safety data from the Phase 2 and 3 clinical trials on the MRX-1 treatment of complex skin and soft tissue infections are significantly different from that of linezolid The ID Week 2022 was held in Washington, D.C., USA, from October 19 to 23, 2022. On October 22, the clinical efficacy and safety data on the high-profile contezolid (CZD/MRX-1) and its prodrug CZA (MRX-4) in four Phase 2 and 3 clinical trials for treatment of skin and soft tissue infections in multiple subpopulations was published through a poster session at the ID Week. The data showed that CZD/CZA had similar clinical efficacy and safety across subpopulations; they showed a hematology-related safety advantage compared with similar drugs. In a poster titled "Phase 2 and 3 Clinical Trials for the Efficacy and Safety of CZD and CZA in Skin Infection Patients across BMI and Gender", the data from four completed Phase 2 and 3 clinical trials on skin and soft tissue infections…